The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation

Alessandra Roberto, Clara Di Vito, Elisa Zaghi, Emilia Maria Cristina Mazza, Arianna Capucetti, Michela Calvi, Paolo Tentorio, Veronica Zanon, Barbara Sarina, Jacopo Mariotti, Stefania Bramanti, Elena Tenedini, Enrico Tagliafico, Silvio Bicciato, Armando Santoro, Mario Roederer, Emanuela Marcenaro, Luca Castagna, Enrico Lugli, Domenico Mavilio

Research output: Contribution to journalArticlepeer-review


Natural killer cells are the first lymphocyte population to reconstitute early after non-myeloablative and T cell-replete haploidentical hematopoietic stem cell transplantation with post-transplant infusion of cyclophosphamide. The study herein characterizes the transient and predominant expansion starting from the second week following haploidentical hematopoietic stem cell transplantation of a donorderived unconventional subset of NKp46neg-low/CD56dim/CD16neg natural killer cells expressing remarkably high levels of CD94/NKG2A. Both transcription and phenotypic profiles indicated that unconventional NKp46neg-low/CD56dim/CD16neg cells are a distinct natural killer cell subpopulation with features of late stage differentiation, yet retaining proliferative capability and functional plasticity to generate conventional NKp46pos/CD56bright/CD16neg-low cells in response to interleukin-15 plus interleukin-18. While present at low frequency in healthy donors, unconventional NKp46neg-low/CD56dim/CD16neg cells are greatly expanded in the seven weeks following haploidentical hematopoietic stem cell transplantation, and express high levels of the activating receptors NKG2D and NKp30 as well as of the lytic granules Granzyme-B and Perforin. Nonetheless, NKp46neg-low/CD56dim/CD16neg cells displayed a markedly defective cytotoxicity that could be reversed by blocking the inhibitory receptor CD94/NKG2A. These data open new and important perspectives to better understand the ontogenesis/homeostasis of human natural killer cells and to develop a novel immune-therapeutic approach that targets the inhibitory NKG2A check-point, thus unleashing natural killer cell alloreactivity early after haploidentical hematopoietic stem cell transplantation.

Original languageEnglish
Pages (from-to)1390-1402
Number of pages13
Issue number8
Publication statusPublished - Jul 31 2018

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The early expansion of anergic NKG2A<sup>pos</sup>/CD56<sup>dim</sup>/CD16<sup>neg</sup> natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this